MDLive review
MDLIVE offers anti-obesity prescriptions through eligible Primary Care Routine Care visits. Its urgent-care service and wellness screening are different pathways.
The verdict
The crucial distinction is the appointment type. MDLIVE lists anti-obesity medicines as possible through Primary Care Routine Care, with clinical discretion and state exclusions. Booking urgent care simply because it is available sooner does not provide the same weight-management service.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide · Liraglutide
- Form
- Injection
- Prescription
- Required
MDLIVE is a virtual-care platform whose independent professional entities provide clinical services. Its public medication policy names options such as Zepbound, Wegovy and Saxenda within the primary-care pathway. That is a broader care model than a standalone medication storefront.
Who writes the prescription, and what do they see?
A medical provider decides whether an anti-obesity prescription is medically appropriate. MDLIVE’s terms separate the platform from the independent clinicians. The medicine list is not a guarantee of a particular drug, dose or an approved claim.
Weight-management prescribing is limited to a Primary Care Routine Care visit. It is not offered through Urgent Care or a Primary Care Wellness Screening. Before booking, verify that the account benefit includes the correct service and that the provider can address the intended condition.
What happens when the dose goes up?
Continuing dose and monitoring decisions sit with the primary-care clinician. The public medication policy does not define one universal GLP-1 escalation or refill schedule. Ask how later appointments are arranged, who reviews side effects and whether the same care team can follow the course.
What the price includes
Visit costs depend on the service and benefit arrangement; the public pages do not establish an all-in monthly GLP-1 bill. Pharmacy medication, laboratory requirements and plan cost-sharing must be considered separately. Cancellation fees may apply and are disclosed before booking.
What it claims, and what it cites
The published anti-obesity examples include semaglutide, tirzepatide and liraglutide brands. They are unavailable through this pathway in Florida, Louisiana, Mississippi and New Jersey under the posted policy. A general statement about nationwide virtual care does not override that restriction.
Where it holds up, and where it does not
- Strength: Clear prescribing eligibility by appointment type
- Strength: Primary-care context for ongoing conditions
- Strength: Medication exclusions are disclosed
- Limitation: Urgent care cannot substitute for Routine Care
- Limitation: Four states excluded from this prescribing pathway
- Limitation: No public inclusive medication price
What the evidence says about this kind of treatment
The assessment above is about MDLive. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- Someone whose benefits include MDLIVE primary care and who wants a clinician to assess weight treatment in that setting.
- Wrong for
- A patient in an excluded state or someone trying to obtain weight-loss medication through a rapid urgent-care appointment.
The evidence behind what MDLive prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How MDLive compares
| Seller | Who it suits | Go |
|---|---|---|
| SkinnyRx | Readers choosing tirzepatide, the one line with a published standing rate | See SkinnyRx → |
| ShedRx | Readers willing to telephone a seller and ask which published fee is the real one | See ShedRx → |
| RxSpan MD | Buyers who want the standing rate, the pharmacy and the prescriber named before signing up | See RxSpan MD → |
More GLP-1 telehealth sellers reviews: WillowYourEraEverPrimeMyDrHank1st Optimal24hrDOC
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Can urgent care prescribe these weight-loss drugs?
- MDLIVE says anti-obesity medication is available only through Primary Care Routine Care, not its other visit types.
- Which states are excluded?
- The posted policy excludes Florida, Louisiana, Mississippi and New Jersey for this anti-obesity prescribing pathway.
- Is the medication included in a visit?
- The public information does not establish a bundled medicine price. Check the visit benefit and pharmacy charges separately.
Sources for this review
Provider information checked . Terms can change.